logo

Eagle Pharmaceuticals Inc (EGRX)



Trade EGRX now with
  Date
  Headline
6/11/2018 7:19:28 AM Eagle Pharma Says Generic TREANDA Entry Now Not Expected Until December 2022
5/16/2018 6:50:50 AM Eagle Pharma Granted FDA Approval For Bendamustine Hydrochloride Ready-to-Dilute Solution In A 500ml Admixture
5/10/2018 6:51:58 AM Eagle Pharma Q1 Net Income $2.6 Mln Or $0.17/shr Vs. $22.9 Mln Or $1.42/shr Prior Year
4/16/2018 7:07:12 AM Eagle Pharmaceuticals’ Vasopressin ANDA Accepted For Filing By FDA
2/26/2018 6:57:46 AM Eagle Pharma Posts Q4 EPS Of $0.58; Adj EPS Of $1.00
12/7/2017 6:52:43 AM Eagle Pharma Begins Pivotal Study For Fulvestrant
11/8/2017 6:52:15 AM Eagle Pharmaceuticals Q3 EPS $0.98 Vs $0.73 Last Year
10/17/2017 7:34:53 AM Eagle Pharmaceuticals Announces New Patent For RYANODEX
9/20/2017 6:55:09 AM Eagle Licenses Japanese Rights For Bendamustine Hydrochloride Rapid Infusion Injection Products To SymBio
8/9/2017 6:51:40 AM Eagle Pharma Q2 Revenue Grows 22% Year-over-year To $50.1 Mln
7/27/2017 12:32:35 PM William Blair Is Lowering Eagle Pharmaceuticals Inc (EGRX) FY18 Estimate To 3.23 From 3.83
7/27/2017 12:32:20 PM William Blair Is Lowering Eagle Pharmaceuticals Inc (EGRX) FY17 Estimate To 3.29 From 3.80
7/27/2017 12:31:59 PM William Blair Is Cutting Eagle Pharmaceuticals Inc (EGRX) FY18 Rev. Estimate To 235.2 M From 284.1 M
7/27/2017 12:31:38 PM William Blair Is Cutting Eagle Pharmaceuticals Inc (EGRX) FY17 Rev. Estimate To 245.9 M From 268.0 M
7/27/2017 10:19:39 AM RBC Capital Markets Is Lowering Eagle Pharmaceuticals Inc (EGRX) 2019 Rev. Estimate To 388.6 M From 414.6 M
7/27/2017 10:19:28 AM RBC Capital Markets Is Lowering Eagle Pharmaceuticals Inc (EGRX) 2018 Rev. Estimate To 201.1 M From 252.3 M
7/27/2017 10:19:17 AM RBC Capital Markets Is Cutting Eagle Pharmaceuticals Inc (EGRX) 2017 Rev. Estimate To 232.2 M From 252.2 M